my Prenatal

The most comprehensive non-invasive prenatal test

myPrenatal

The genomic revolution of the NIPT

Veritas launches a new generation of Non-Invasive Prenatal Test (NIPT), maximizing the screening performance for common trisomies. The test also provides other analysis options to expand the screening including relevant alterations in the fetal genome.

A new generation of NIPT - myPrenatal GenomeScreen

Veritas offers a prenatal screening for the most common aneuploidies (21, 18, 13, X and Y), also offering the possibility to expand the screening to include:

- **Large deletions and duplications (CNVs) of more than 7 Mb,** alterations that may cause several fetal anomalies associated with delayed cognitive development.
- **Aneuploidies in all chromosomes,** associated with fetal loss and other structural alterations.

High accuracy analysis

myPrenatal provides excellent sensitivity and specificity values by using **the latest generation technology.** This provides great reliability to **reduce unnecessary invasive procedures.**

Prenatal experts

Veritas has an internationally **renowned team of experts in both genetic counselling and prenatal diagnosis** to support physicians with the assessment of results.

myPrenatal - Reliable results even with low fetal fraction

myPrenatal bioinformatic algorithm combines the **fetal DNA fraction and sequencing depth to achieve highly reliable results** in cases of low fetal fraction, reducing the rate of no-call results.

Available for singleton and twin pregnancies

It is possible to request the analysis of c**ommon aneuploidies and the GenomeScreen option for both singleton and twin pregnancies.** The analysis of sex chromosomes aneuploidies can only be performed in singleton pregnancies.

NGS paired-end sequencing

NGS paired-end sequencing allows the discrimination of fetal and maternal cell-free DNA, **improving the fetal fraction assessment and bioinformatic analysis**, thus increasing test performance.

CE-IVD marked and performed in Europe

The test is performed in **our laboratories located in Europe** by an experienced team and is **CE-IVD marked.**

Common Trisomies



Sex Chromosome Aneuploidies



Síndrome Klinefelter

GenomeScreen: CNVs and aneuploidies in all autosomal chromosomes





Veritas offers the most comprehensive service of prenatal genetic counselling to the physician.

Performance

	Trisomy 21	Trisomy 18	Trisomy 13	Rare aneuploidies	Partial Del/dup
Sensitivity[1]	>99,9%	>99,9%	>99,9%	96,4%	74,1%
Specificity[1]	99,90%	99,90%	99,90%	99,80%	99,80%

Fetal sex concordance		
100% XX, XY, XXX, XXY	90,5% XO	91,7% XYY

myPrenatal – More accurate results

myPrenatal bioinformatic algorithm **assesses fetal fraction and sequencing depth** to deliver the best performance in all cases. In cases with low fetal fraction, results can be delivered with the same accuracy as in cases with a higher fetal fraction, if there is an appropriate sequencing depth. If the fetal fraction is high, the analysis requires a lower sequencing depth.

Other tests



Arbitrary fetal fraction limit of 4%, below this limit no results are delivered. This may occur in about 5% of cases[2]. The percentage of trisomies in samples with a fetal fraction <4% is significantly higher than in samples with higher fetal fractions[3].

myPrenatal



There is no established limit of fetal fraction. In cases with low fetal fraction with appropriate sequencing depth, it is possible to deliver reliable results, improving the sensitivity for detection of aneuploidies.



Bibliography:

1) Illumina. VeriSeq NIPT Solution v2 Package Insert. 2020.
2) Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372(17):1589-1597.
3) Revello R, Sarno L, Ispas A, et al. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound Obstet Gynecol. 2016;47(6):698-704.

Different options for the healthcare provider

my Prenatal	• Trisomy 21 - Down syndrome • Trisomy 18 - Edwards syndrome • Trisomy 13 - Patau syndrome	• Fetal sex determination[1]
my PrenatalXY	• Trisomy 21 - Down syndrome • Trisomy 18 - Edwards syndrome • Trisomy 13 - Patau syndrome	• Fetal sex determination[1] • Analysis of sex chromosomes aneuploidies (XO, XXX, XXY, XYY)[2]
my Prenatal GENOME-SCREEN	• Trisomy 21 - Down syndrome • Trisomy 18 - Edwards syndrome • Trisomy 13 - Patau syndrome • Analysis of partial deletions and duplications >7Mb (CNVs) [3]	• Fetal sex determination[1] • Analysis of sex chromosomes aneuploidies (XO, XXX, XXY, XYY)[2]
my Prenatal GENOME-SCREEN All Chromosomes	• Trisomy 21 - Down syndrome • Trisomy 18 - Edwards syndrome • Trisomy 13 - Patau syndrome • Analysis of partial deletions and duplications >7Mb (CNVs) [3] • Analysis of rare autosomal aneuploidies (all autosomal chromosomes)	• Fetal sex determination[1] • Analysis of sex chromosomes aneuploidies (XO, XXX, XXY, XYY)[2]

Suitable for singleton and twin pregnancies

[1] In case of a twin pregnancy only the presence of Y chromosome will be analysed; [2] Sex chromosomes aneuploidies analysis is only available for singleton pregnancies; [3] The analysis of the CNVs (Copy Number Variants) are limited to the autosomal chromosomes (not sexual). CNVs larger than 7Mb are generally related to fetal anomalies and developmental delay.



- Veritas offers genetic counselling to the healthcare provider as part of the service provided.
- Moreover, if a high risk of CNVs is detected, Veritas includes a clinical interpretation of the result.
- The turnaround time is **5 working days** since the sample arrives to the laboratory.

Veritas
The Genome Company

Leader in DNA sequencing and interpretation
Extensive experience in prenatal medicine
Experts in genetic counselling

About Veritas

Veritas Genetics, a LetsGetChecked company, is one of the world leaders in advanced genetic sequencing and clinical interpretation of the exome and whole genome, driving the transition to personalized and preventive medicine.

Using state-of-the-art technologies and the highest safety standards, Veritas Genetics helps individuals, healthcare professionals and institutions worldwide to understand and anticipate genetic risks, enabling more informed and proactive health decisions.

With a focus on innovation and accessibility, Veritas Genetics transforms the way we understand and care for health at every stage of life.

Veritas combines the most innovative new technology with clinical genetic expertise to offer physicians a comprehensive healthcare service during and after pregnancy.

my Newborn | The genetic screening test that allows personalizing the newborn's medical care from the first day of life.

Veritas
a LetsGetChecked company

info@veritasint.com | veritasint.com

MB.MP_EN_V2.5
10/02/2025